High Clarithromycin Resistance and a Low Rate of Recurrence and Reinfection of Helicobacter pylori Infection in Pakistan by Abid, Shahab et al.
eCommons@AKU
Section of Gastroenterology Department of Medicine
May 2012
High Clarithromycin Resistance and a Low Rate of
Recurrence and Reinfection of Helicobacter pylori
Infection in Pakistan
Shahab Abid
Aga Khan University, shahab.abid@aku.edu
javed Yakoob
Aga Khan University, javed.yakoob@aku.edu
Wasim Jafri
Aga Khan University, wasim.jafri@aku.edu
Z Abbas
Aga Khan University, zaigham.abbas@aku.edu
Khalid Mumtaz
Aga Khan University, khalid.mumtaz@aku.edu
See next page for additional authors
Follow this and additional works at: http://ecommons.aku.edu/
pakistan_fhs_mc_med_gastroenterol
Part of the Gastroenterology Commons
Recommended Citation
Abid, S., Yakoob, j., Jafri, W., Abbas, Z., Mumtaz, K., Hamid, S., Ahmed, R. (2012). High Clarithromycin Resistance and a Low Rate of
Recurrence and Reinfection of Helicobacter pylori Infection in Pakistan. Gastroenterology, 142(5), S-488-S-488.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_med_gastroenterol/144
Authors
Shahab Abid, javed Yakoob, Wasim Jafri, Z Abbas, Khalid Mumtaz, Saeed Hamid, and Rashida Ahmed
This article is available at eCommons@AKU: http://ecommons.aku.edu/pakistan_fhs_mc_med_gastroenterol/144
Su1711
Reliable Efficacy of 14-Day High Dose PPI Triple Therapy for Helicobacter
pylori Eradication in Non -Ulcer Dyspeptic Patients in Thailand
Sanchai Prasertpetmanee, Varocha Mahachai, Ratha-korn Vilaichone
Background and aim:The eradication rate of standard triple therapy for H. pylori has decreased
worldwide including Thailand. Newer regimen is required to achieve better outcome. The
study was designed to determine the eradication rate of 7-day and 14-day high dose PPI
triple therapy for H. pylori infection in Thai patients with non-ulcer dyspepsia. METHODS:
Between September 2010-November 2011, patients who underwent gastroscopic examina-
tion at the Thammasat University Hospital, for dyspeptic symptoms were recruited. Two
biopsy samples from gastric antrum were obtained, one for rapid urease test and another
for culture. Patients were randomized to receive 7 days or 14 days high dose PPI triple
therapy which consisted of lansoprazole 60 mg twice daily, amoxicillin 1 g twice daily, and
clarithromycin 500 mg twice daily. UBT was performed 6 weeks after therapy to assess
eradication. RESULTS:A total of100 patients were enrolled in this study including 35 males
and 65 females with mean age of 53 years. All patients completed both regimens therapy
without significant side effects. The culture was successful in 20 patients and demonstrated
40% of metronidazole resistant and 4 % of clarithromycin resistant strains. The efficacy of
14-day high dose PPI triple therapy was 100 % (50/50 patients) and was significantly higher
than 7-day high dose PPI triple therapy (44/50 patients) (100% vs 88%; P-value <0.05).
Minor side effects were reported including bitter taste and nausea (10%) and palpitation
after taking clarithromycin (4%) CONCLUSIONS: The 14-day high dose PPI triple therapy
provide a high eradication rate than 7-day high dose PPI triple regimen. This 14-day high
dose PPI triple regimen is well tolerated, highly effective with only minor side effects and
should be used as first line H. pylori eradication in Thailand.
Su1712
Superiority of Bismuth-Based Quadruple Therapy vs. Standard Triple Therapy
for Empiric Primary Treatment of Helicobacter pylori Infection: Systematic
Review and Meta-Analysis of Efficacy and Tolerability
Marino Venerito, Tina Krieger, Thomas Ecker, Peter Malfertheiner
Background: In areas of clarithromycin resistance >15% clarithromycin-based standard triple
therapy is no longer a good first choice regimen for Helicobacter pylori (H. pylori) eradication.
Randomized controlled trials (RCTs) comparing proton pump inhibitor (PPI), bismuth,
tetracycline, and metronidazole (quadruple therapy) vs. PPI, clarithromycin, and amoxicillin
(triple therapy) suggest that quadruple therapy may replace triple therapy for first-line
treatment. Aim: We performed a systematic review and meta-analysis to compare the efficacy
and tolerability of these two regimens as first-line treatment of H. pylori infection. Methods:
A search of MEDLINE, EMBASE, and Cochrane Library for English language literature
was carried out. Randomized controlled trials (RCTs) comparing bismuth-based quadruple
therapy to clarithromycin-based triple therapywere selected formeta-analysis. Data extraction
was performed by two independent reviewers, using standardized data forms. Statistical
analysis was conducted with RevMan 5.1 software. Forest plots, Funnel plots and subgroup
analyses were carried out. Results: The search strategy identified a total of 39 references.
Nine papers were included in the analysis. Dosing regimens of triple therapy were quite
consistent among trials (clarithromycin 1000 mg/d, amoxicillin 2000 mg/d), but varied
considerably for quadruple therapy (bismuth 240-1680 mg/d, metronidazole 400-1500 mg/
d, tetracycline 1500-2000 mg/d). Bismuth-based quadruple therapy achieved eradication in
81.1 % of patients, whereas clarithromycin-based triple therapy achieved an eradication rate
of 69.9 % (odds ratio (OR) =1.86, 95% confidence interval (CI): 1.18-2.92, p=0.008). There
was no evidence for significant publication bias. Different duration of treatment regimens
(7, 10 or 14 days for each regimen in different combinations) account for the high heterogen-
eity among the studies (I2=76%). Heterogeneity was 0% when only the subgroup of trials
evaluating standardized quadruple therapy (bismuth 1680 mg/d, metronidazole 1500 mg/
d, tetracycline 1500 mg/d, PPI 20 mg/bid for 10 days) vs. standard triple therapy for 7
days was considered. In the sensitivity analysis, standardized quadruple therapy achieved
eradication in 91.1% of patients, whereas standard triple therapy achieved an eradication rate
of 67.1% (OR=5.03, 95% CI: 3.17-7.98, p=0.00001). There were no statistically significant
differences in side effects yielded by quadruple vs. triple therapy (OR = 0.92, 95 % CI: 0.76
-1.12). Conclusions: Bismuth-based quadruple therapy yielded higher eradication rates as
primary therapy for H. pylori infection compared to clarithromycin-based triple therapy.
Standardized quadruple therapy achieved eradication rates >90% and should therefore be
considered for first-line treatment of H. pylori infection.
Su1713
Analytical Equivalence Study of NDIRS Versus IRMS in Breath Test Analysis
Mitchell R. Lie, Sjam. Ganesh, Jelle Haringsma, Jan Francke, Ernst J. Kuipers
Background. Several techniques exist regarding the diagnosis of Helicobacter pylori infection.
Nowadays, urea breath tests (13C-UBT) are the preferred non-invasive test for detecting H.
pylori before and after treatment. Initially, the 13C-UBT measurements are performed using
isotope ratio mass spectrometer (IRMS). However, the newer developed nondispersive iso-
tope-selective infrared spectrophotometer (NDIRS) device has the advantage of lower operat-
ing costs and being easier in use. However it is uncertain whether the NDIRS method is as
accurate as the IRMS method, especially with the commercially available 13C-urea kits for
HP-testing. The objective of this study was to evaluate the NDIRS as a suitable and reliable
replacement for analysis of 13C-urea breath test samples using the commercially available
13C-UBT-kit, compared with the accepted IRMS analysis method. Methods. A multi-center,
open-label study was performed in two large hospitals, according to GCP guidelines. Patients
referred for 13C-UBT were given 100mg of 13C-urea. Baseline and 30 minute breath samples
were obtained in two mediums; one was analyzed with NDIRS, the other with IRMS. No
other test was performed to confirm the H. pylori status. Results. 43 patients were entered
into the study. IRMS tested 13 patients as positive and 30 patients as negative for H. pylori.
NDIRS found 14 patients positive and 39 negative. Compared to IRMS, NDIRS showed a
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positive predictive value of 100%, a negative predicitive value of 96.7% (95% CI 0.83-
1.00), a sensitivity of 92.9% (95% CI 0.66-1.00) and specificity of 100%. The total agreement
rate was 98% (42 out of 43), with a correlation coefficient (r) of 0.9796. The only disconcord-
ant outcome probably resulted from faulty breath sampling in the IRMS medium, causing
a false negative IRMS result. Conclusions. In this study, NDIRS and IRMS appear equally
accurate in detecting Helicobacter infection. Therefore it seems that the NDIRS is justified
as an alternative method for analysing 13C-urea breath test samples. Given the greater ease
of use and lower costs, NDIRS could even be preferred over IRMS for analysis of 13C-urea
breath test samples. The commercial available 13C-urea test kit appears to be suitable for
HP-test with NDIRS.
NDIRS test results compared with IRMS test results. Assuming IRMS as gold standard,
NDIRS has a positive predictive value of 100%, a negative predicitive value of 96.7% (95%
CI 0.83-1.00), a sensitivity of 92.9% (95% CI 0.66-1.00) and specificity of 100%.
Su1714
High Dose Amoxicillin-Based First Line Regimen Compared to Sequential
Therapy in the Eradication of H. pylori Infection
Francesco Franceschi, Annalisa Tortora, Mariachiara Campanale, Flavio Bertucci, Silvia
Pecere, Viviana Gerardi, Federico Barbaro, Giovanni Gigante, Valentina Cesario, Paolo
Iacomini, Anna Granato, Chiara Cordischi, Marta Sabbatini, Niccolò Gentiloni Silveri,
Diego Curro', Giovanni Cammarota, Giovanni Gasbarrini, Antonio Gasbarrini
BACKGROUND: Helicobacter pylori eradication rates with standard first-line triple therapy
have declined to unacceptable levels. Ten days sequential therapy has been shown to increase
eradication rate and is now considered to be one of the best options as-first line treatment.
To date, amoxicillin-resistant H. pylori strains have rarely been detected. Whether increasing
the dosage of amoxicillin in a standard 7 days eradicating regimen may enhance the efficacy
is not known. AIM: To compare the efficacy of a 7 days high-dose amoxicillin based first-
line regimen with sequential therapy. METHODS: 300 sex and age matched patients were
randomized into 3 different therapeutic schemes: (1) standard LCA, lansoprazole 15 mg
bid, clarithromycin 500 mg bid and amoxicillin 1000 mg bid for 7 days; (2) high dose LCA
(HD-LCA), lansoprazole 15 mg bid, clarithromycin 500 mg bid and amoxicillin 1000 mg
tid for 7 days; (3) sequential LACT, lansoprazole 15 mg bid plus amoxicillin 1000 mg bid
for 5 days, followed by lansoprazole 15 mg bid, clarithromycin 500 mg bid and tinidazole
500 mg bid for 5 days. Eradication was confirmed by 13C-urea breath test. Compliance
and occurrence of adverse effects were assessed by a validated questionnaire. RESULTS:
Eradication rates were: LCA (55% PP, 53% ITT), HD-LCA (75% PP, 72% ITT), LACT (73%
PP; 72% ITT). Eradication rates were higher in HD-LCA group compared to LCA (p<0.01),
while no significant differences were observed in HD-LCA group compared to LACT (p=
ns). Compliance and occurrence of adverse effects was similar among groups. CONCLU-
SIONS: High dose amoxicillin based eradicating treatment is superior to standard triple
therapy and equivalent to sequential therapy; compared to the latter, the shorter duration
may represent an advantage
Su1715
Substitution of Tetracycline by Amoxicillin in Second-Line Helicobacter pylori
Treatment Conveys Comparable Success Rates
Spyridon Michopoulos, Evanthia Zampeli, Panayiotis Anapliotis, Michael Mavros,
Charalambos Giannopoulos, Vassilios Xourafas, Vasiliki Kalampoki
Introduction: According to Maastricht III consensus, bismuth (Bis) based quadruple (QUAD)
therapy is the preferred second choice treatment for Helicobacter pylori (Hp) eradication, if
not previously used. Additionally, it is advisable to avoid antibiotics that were included in
the initial therapeutic scheme. The regular Bis-containing quadruple therapy comprises a
proton pump inhibitor (PPI), tetracycline (TETRA) and metronidazole (M). However, TETRA
is not always available, side effects are often not well tolerated and doxycycline's efficacy is
questionable. The aim of our study was to compare the efficiency of amoxicillin (AMO)
when administered instead of TETRA in patients who failed to eradicate Helicobacter pylori
(Hp) on a previous treatment containing AMO. Patients and methods: We retrospectively
reviewed the records of 98 consecutive patients who failed 10-days standard triple therapy
with PPI + clarithromycin + AMO. All patients received a 14- days QUAD regimen with
PPI bid + Colloidal Bismuth Subcitrate (CBS) 300mg tid + Metronidazole (M) 500mg tid
and either TETRA 500mg tid (group A) or AMO 1gr bid (group B). Response to treatment
was evaluated with urea breath test (UBT) that was performed no sooner than a month after
completion of eradication therapy. Results: 89 patients were eligible for analysis (45 in group
A and 44 in group B). Demographics were comparable among the 2 groups. The results of
the intention to treat (ITT) and the per protocol (PP) analysis are shown in the table. No
statistically significant differences were revealed.Conclusions: 1) Substitution of Tetracycline
by Amoxicillin in a bismuth- containing quadruple, second-line scheme does not affect
eradication rate. 2) This is true for first line regimens that include AMO 3) In case of
Tetracycline shortage or intolerance, Amoxicillin may be a good alternative with at least
comparable results.
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